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Background. We evaluated the effectiveness and cost-effectiveness of interventions targeting hepatitis C virus (HCV) and HIV 
infections among people who inject drugs (PWID) in Eastern Europe/Central Asia. We specifically considered the needle-syringe 
program (NSP), opioid substitution therapy (OST), HCV and HIV diagnosis, antiretroviral therapy (ART), and/or new HCV treat-
ment (direct acting antiviral [DAA]) in Belarus, Georgia, Kazakhstan, Republic of Moldova, and Tajikistan.
Methods. We developed a deterministic dynamic compartmental model and evaluated the number of infections averted, costs, 
and incremental cost-effectiveness ratios (ICERs) of interventions. OST decreased frequencies of injecting by 85% and NSP needle 
sharing rates by 57%; ART was introduced at CD4 <350 and DAA at fibrosis stage ≥F2 at a $2370 to $23 280 cost.
Results. Increasing NSP+OST had a high impact on transmissions (infections averted in PWID: 42% in Tajikistan to 55% in 
Republic of Moldova for HCV; 30% in Belarus to 61% in Kazakhstan for HIV over 20 years). Increasing NSP+OST+ART was very 
cost-effective in Georgia (ICER  =  $910/year of life saved [YLS]), and was cost-saving in Kazakhstan and Republic of Moldova. 
NSP+OST+ART and HIV diagnosis was very cost-effective in Tajikistan (ICER = $210/YLS). Increasing the coverage of all interven-
tions was always the most effective strategy and was cost-effective in Belarus and Kazakhstan (ICER = $12 960 and $21 850/YLS); it 
became cost-effective/cost-saving in all countries when we decreased DAA costs.
Conclusion. Increasing NSP+OST coverage, in addition to ART and HIV diagnosis, had a high impact on both epidemics and 
was very cost-effective and even cost-saving. When HCV diagnosis was improved, increased DAA averted a high number of new 
infections if associated with NSP+OST.
Keywords. cost-effectiveness; Eastern Europe & Central Asia; hepatitis C; HIV; people who inject drugs.
 
Eastern Europe and Central Asia (EECA) is a region where epi-
demics of HIV/AIDS and chronic hepatitis C have grown rap-
idly in recent years. In 2013, 1.1 million HIV-infected people 
were estimated to live in EECA, with 110 000 new annual infec-
tions overall [1]. This accounted for an increase of almost 100% 
new cases per year since 2003. In these countries, a high pro-
portion of those infected with HIV and hepatitis C virus (HCV) 
are people who inject drugs (PWID), because of needle sharing 
in particular. In 2013, 9 of the 16 countries of EECA had an HIV 
prevalence among PWID above 10%, such in Estonia, Ukraine, 
and Belarus In Russian Federation, it was estimated that 16% 
(320 000) of PWID were infected by HIV in 2009 [2]. Regarding 
HCV, it was estimated that 2.3 million PWID were infected in 
Eastern Europe in 2013, with a prevalence higher than 50% 
in this population in countries such as Georgia, Kazakhstan, 
Russian Federation, and Ukraine [3, 4].
Because of this high prevalence among PWID, HIV and 
HCV prevention strategies must target this population to 
contain the epidemics in the whole country. Programs have 
been initiated to reduce the incidence of these infections 
among PWID. Needle-syringe programs (NSPs) are one of 
the most frequent and efficacious strategies, and they consist 
of distributing sterile injecting equipment among PWID, but 
coverage remains low in EECA [5]. Another strategy consists 
in providing PWID with opioid substitution therapy (OST) 
to reduce the risk of infected needle sharing. Although this 
strategy combined with other interventions has proved to be 
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effective and cost-effective in Western countries [6–8], its use 
remains very limited in EECA [1]. In some countries of EECA, 
there is still no OST program in place (Uzbekistan), and such 
programs are even legally prohibited (Russian Federation, 
Turkmenistan) [1].
Few analyses on the cost-effectiveness of these interventions 
among PWID in EECA countries have been reported. In add-
ition, they have only concerned HIV infection in specific coun-
try settings [8–12]. Most studies have evaluated the impact of 
individual strategies and not the simultaneous implementation 
of strategies such as NSP, OST, HCV/HIV screening, access to 
anti-HCV treatment, and antiviral therapy (ART), specifically 
in the enlarged EECA region [10–13].
The objective of this study was to evaluate the comparative 
costs, effectiveness, and cost-effectiveness of interventions 
among PWID in averting new HCV and HIV infections and 
HCV- and AIDS-related deaths in 5 countries in Eastern Europe 
and Central Asia: Belarus, Georgia, Kazakhstan, Republic of 
Moldova, and Tajikistan.
METHODS
Analytic Overview
We developed a dynamic compartmental model to simulate the 
probability of HIV and HCV transmission and the natural his-
tory of these diseases in PWID and non-PWID (NPWID) in the 
5 countries studied. We estimated the impact of different strate-
gies from 2013 to 2033. The strategies differed according to the 
level of single and combined interventions: the increase of NSP 
and OST coverage, HIV and HCV diagnosis, and access to HIV 
and HCV treatment. An additional scenario was simulated to 
evaluate a “what if ” situation when the coverage of interven-
tions would have been very limited or fallen back to very low 
levels. Supplementary Table 1 details the set of strategies con-
sidered and their direct impact on the outcomes.
Outcomes included projected cumulative number of new 
HCV and HIV infections among PWID and NPWID, total 
costs related to interventions and HCV and HIV care, years of 
life saved (YLS), and the incremental cost-effectiveness ratio 
(ICER) measured in 2013 USD per years of life saved ($/YLS). 
A strategy was labeled “cost-effective” if its ICER was less than 
3 times the nation’s gross domestic product (GDP) per capita, 
as recommended by World Health Organization (WHO) [14]; 
“very cost-effective” if less than 1x GDP/capita; “cost-saving” if 
less expensive and more effective than the reference; and “dom-
inated” if more expensive and less effective than the reference. 
Costs and YLS were discounted using a 0.03 per annum rate [14].
The Model Structure 
We simulated the population moving between injecting sta-
tuses: non-PWID; PWID using neither NSP nor OST; PWID 
using NSP but not OST; and PWID using OST. PWID moved to 
the NSP compartment if they received more than 100% of their 
injections (Figure 1) [15]. Individuals entered the model at age 
15  years [16] and were neither PWID nor infected with HIV 
and HCV; they exited when they died or passed age 65 years.
Both natural histories of HIV and HCV infection included 
“undiagnosed,” “diagnosed,” and “in treatment” states. Hepatitis 
C progressed through fibrosis stages aggregated into 3 com-
partments: F0-F1, F2-F3, and F4. When diagnosed, HCV treat-
ment was initiated at F2 considering new direct acting antiviral 
(DAA) regimens. Patients could clear the virus spontaneously 
in stage F0-F1 or when treated, based on HCV treatment effi-
cacy. Patients in stage F4 could develop complications such 
decompensated cirrhosis or hepatocellular carcinoma. For HIV, 
firstline treatments were initiated for diagnosed patients with a 
CD4 count below 350 cells/mm3, because in 2013 ART was still 
initiated according to this threshold. On efficacious treatment, 
patients moved into the CD4>350 category. Patients moved to 
the ART failure category when all available ART regimens failed 
considering a probability based on treatment regimens available 
in each country. The model allowed HIV/HCV co-infections.
Transmission
HIV and HCV transmission occurred though syringe sharing 
but differed according to NSP status, estimated to decrease by 
50% the risk of transmission in PWID receiving 100% of their 
injection [15], and OST status, considered to reduce by 83% 
the number of injections per year [6]. The forces of infection 
were calculated according to baseline risks of transmission per 
contaminated syringe for HIV [17] and HCV [6], the annual 
number of injections per PWID, the total number of syringes 
distributed by NSP, the number of PWID reached by NSP and 
OST, and the number of PWID on ART and/or DAA.
HIV transmission also occurred through sexual contact, as 
well as HCV transmission, but at a very low risk. The forces 
of infection were calculated according to baseline risks of 
transmission per sexual act for HIV [17, 18] and HCV [19], 
the mean number of sexual intercourse acts per person, the 
condom use rate and its efficacy [12, 20], and the number of 
injecting drug partners, considering the affinity rate among 
PWID [9, 21]. We also considered the relative risk reduction 
(RRR) of sexual transmission for HIV-infected patients on 
ART [9, 12] and/or HCV-infected patients on DAA. HCV-
infected patients with sustained viral response had a zero risk 
of HCV transmission.
Input Parameters
Input parameters were derived from the international literature 
and data collections initiated by teams in each country who 
provided country-specific parameters: HIV and HCV preva-
lence, injecting and sexual behavior, and intervention coverage, 
as well as costs of interventions and costs of HIV and HCV care 
per patient per year (Table 1). Because new DAAs were not yet 
available in the countries, we hypothesized that costs were equal 
to 2013 treatment costs.
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Sensitivity Analyses
Extensive sensitivity analyses were conducted to evaluate the 
impact of uncertainty surrounding key parameters to validate 
the robustness of results. We also evaluated the impact in terms 
of cost-effectiveness of “what if ” scenarios regarding the cost of 
new DAAs and treatment initiation criteria.
An extended summary of the input parameters and more 
details on the model structure in costs are presented in the 
Supplementary Material.
RESULTS
Effectiveness
The impact on the number of new HCV infections averted 
(Figure  2A, B) compared with the current strategy was the 
highest, with the strategy increasing NSP, OST, HCV screen-
ing, and access to new DAAs (infections averted in PWID: 50% 
in Tajikistan to 70% in Republic of Moldova; NPWID: 3% in 
Tajikistan to 28% in Belarus). When considering strategies that 
PWID
no NSP or OST
PWID
on OST
not-
PWID
PWID
NSP no OST
Clearance
B
A
C
Clearance
On treatment
F2-F3
F0-F1 F2-F3 F4
F0-F1SHCV F2-F3 F4
Comp
F4
Not on treatmentDiagnosed
Undiagnosed
Undiagnosed Diagnosed ART ART failure
CD4>350 CD4>350 CD4>350 CD4>350
CD4<350
HIV
SHIV
CD4<50 CD4<350 CD4<350
HCV
Figure 1. Compartmental model used for the analysis. The population was divided according to (A) the injecting status considering nonusers (NPWID), people who inject 
drugs (PWID) reached by needle-syringe programs (NSPs; no opioid substitution therapy [OST]), opioid substitution therapy (on OST), or none of them (no NSP or OST); (B) 
hepatitis C virus (HCV) status considering uninfected people (SHCV), the natural history of HCV infection (with fibrosis stages F0-F1, F2-F3, F4, and complications [Comp]), 
and the cascade of care (undiagnosed, diagnosed not in treatment, and in treatment); (C) HIV status considering uninfected people (SHIV), the natural history of HIV infection 
(according to the CD4 cell count: CD4 > 350 or CD4 < 350), and the cascade of care (undiagnosed, diagnosed, on antiretroviral therapy [ART], and ART failure). Every possible 
trajectory considered in the modeling is represented by the arrows between each compartment. Respective probabilities of death were also attributed to each compartment.
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increase intervention individually, access to new DAAs had a 
limited impact (infections averted in PWID: 1% in Kazakhstan 
to 15% in Republic of Moldova; in NPWID: 1% in Tajikistan to 
8% in Belarus). The increase of NSP+OST had a high impact 
in particular in PWID (infections averted: 42% in Tajikistan to 
55% in Republic of Moldova; in NPWID: from –3% in Tajikistan 
to 9% in Belarus).
The impact on the number of new HIV infections averted 
(Figure  2C, D) was the highest, with the strategy increasing 
NSP, OST, access to ART and HIV screening (infections averted 
in PWID: 35% in Georgia to 75% in Kazakhstan; NPWID: 1% 
in Georgia to 39% in Kazakhstan). Increasing NSP and OST 
alone had again a high impact on the reduction of new HIV 
infections in PWID (infections averted: 32% in Georgia to 
Table 1. Summary of Specific Parameters by Countries
Parameters (2012–13) Belarus Georgia Kazakhstan Moldova Tajikistan Sourcesa
Population
Population aged 15–65 y 6 739 080 3 120 600 11 504 430 2 628 642 4 927 304 World Bank
Number of PWID 75 000 45 000 116 840 19 400 25 000 UNAIDS
 Number on OST 908 2250 184 310 300 UNAIDS
 Number of syringes distributed 2 400 000 1 021 870 23 000 000 1 887 578 4 981 270 UNAIDS
HCV prevalence in general population 1.5% 6.7% 3.1% 4.9% 4.0% UNAIDS
HCV prevalence in PWID 39.0% (9–39) 51.0% 56.6% 47.2% 25.0% UNAIDS
 % diagnosed 14% (13.5–27) 27% (13.5–27) 14% (13.5–27) 14% (13.5–27) 14% (13.5–27) UNAIDS
 % on DAA 0.001% 0.001% 0.001% 0.001% 0.001% UNAIDS
HIV prevalence in general population 0.35% 0.30% 0.20% 0.30% 0.52% UNAIDS
HIV prevalence in PWID 13.7% 3.0% (3.0–3.45) 8.0% 14.7% 13.5% UNAIDS
 % diagnosed 66% (33–66) 90% 90% 66% 63% UNAIDS
 % of ART-eligible treated among 
HIV-diagnosed
66% 88% 38% 46% 69% UNAIDS
 CD4 count at diagnosis in PWID 361 212 415 254 231 UNAIDS
% of HCV-infected among HIV-infected in PWID 40% 74% 93% 88% 40% UNAIDS
Behavior
Baseline risk of HIV transmission/contaminated 
syringe
0.63% 0.63% 0.63% 0.63% 0.63%  [17]
Baseline risk of HCV transmission/contaminated 
syringe
4.0% 4.0% 4.0% 4.0% 4.0%  [6]
Number of injections per y per PWID 200 180 268 142 400 UNAIDS
Sharing rate (baseline - without NSP) 4.9% (4.9–9.8) 6.7% (6.7–13>4) 6.7% (6.7–13.4) 8.1% (8.1–16.2) 7.4% (7.4–14.8) UNAIDS
RR of transmission if 100% NSP 50% 50% 50% 50% 50%  [15]
RR of injections if OST 17% (15–85) 17% (15–85) 17% (15–85) 17% (15–85) 17% (15–85) Expert opinion [6]
Sexual behavior
Baseline risk of HIV transmission/sexual 
intercourse
0.08% 0.08% 0.08% 0.08% 0.08%  [17, 18]
Baseline risk of HCV transmission/sexual 
intercourse
0.01% 0.01% 0.01% 0.01% 0.01% Assumption [19]
Affinity rate (among PWID) 0.45 0.45 0.45 0.45 0.45  [9, 21]
Costs (2013 USD)b
HIV-diagnosed with CD4 >350/y 365 565 302 659 96 UNAIDS
HIV-diagnosed with CD4 <350/y 365 829 297 659 99 UNAIDS
Average cost of ART/patient/y (1st line) 192 324 1064 316 166 UNAIDS
HCV-diagnosed with F2-F3/y 55 127 179 0 14 UNAIDS
HCV-diagnosed with F4/y 62 498 1078 537 85 UNAIDS
Average costs of complications (decomp.  
cirrhosis and HCC)
3106 1628 5401 764 425 UNAIDS
Average cost of DAA/patient/y (based on 
Peg+Riba)
11 424 
(900–11 424)
23 280 
(900–23 280)
13 105 
(900–13 105)
12 986 
(900–12 986)
2372 (900–2372) UNAIDS
Total cost of OST/patient/y 594 1290 1216 879 540 UNAIDS
Total cost of NSP/PWID/y 114 79 59 73 110 UNAIDS
GDP per capita (2013) $7575 $3602 $13 172 $2230 $1037 World Bank
Abbreviations: 100% NSP, at least 100% of the injections are covered by NSP; ART, antiretroviral therapy; DAA, direct active agent; F0-F4, fibrosis stages 0 to 4; GDP, gross domestic prod-
uct; HCC, hepatocellular carcinoma; NSP, needle-syringe programs; OST, opioid substitution therapy; PWID, people who inject drugs; RR, relative risk. 
aAll country-specific data were collected and validated by UNAIDS partners in each country.
bWhen data were missing or incomplete, we estimated total costs on the basis of data collected by other countries according to respective GDP per capita.
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62% in Kazakhstan; in NPWID: from 1% in Georgia to 20% 
in Kazakhstan). Strategies increasing access to ART and HIV 
screening in PWID also had an impact in NPWID (infections 
averted in PWID: 2% in Georgia to 40% in Republic of Moldova; 
in NPWID: from 0.5% in Georgia to 32% in Kazakhstan).
Cost-effectiveness 
The most effective strategy over 20  years was to increase the 
coverage of all interventions, including NSP, OST, HCV, and 
HIV screening, and access to new DAAs and ARTs: Strategy 9 
for HCV, from 26 000 YLS in Georgia to 210 090 in Kazakhstan; 
Strategy 11 for HIV, from 63 830 YLS in Belarus to 15 470 in 
Republic of Moldova and 33 080 in Tajikistan (Table 2). This full 
combined strategy was also the most expensive ($466 850 000 
and $179 090 000 in Belarus and Tajikistan, respectively, over 
20 years).
In all countries, increasing either ART alone (Strategy 4)  or 
HIV screening and ART (Strategy 5)  was cost-saving com-
pared with the baseline strategy over 20  years. In Belarus and 
Tajikistan, in addition to increasing ART and HIV screening, 
NSP and OST coverage increase (Strategy 8)  was very cost-ef-
fective over 20 years (ICER = $210 and $360/YLS). In Georgia, 
in addition to increasing ART, the increase of NSP and OST 
was very cost-effective compared with the baseline (Strategy 8: 
ICER = $910/YLS). In Kazakhstan and Republic of Moldova, 
increasing ART and HIV screening NSP and OST was cost-saving.
When considering the increase of all interventions, the com-
bined strategy was cost-effective in Belarus (ICER = $12 960/
YLS). The increase of NSP, OST, access to ART, HCV screen-
ing, and access to new DAAs was cost-effective in Kazakhstan 
(ICER = $21 850/YLS). The full combined strategies were not 
cost-effective in Republic of Moldova, Georgia, and Tajikistan.
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Figure 2. Percentage of new infections averted compared with the baseline over 20 years. A and B, The percentage of new HCV infections averted among people who 
inject drugs (PWID) and the general population (NPWID), respectively, when the coverage of interventions against hepatitis C virus (HCV) transmission is increased among 
PWID (including needle-syringe programs [NSPs], opioid substitution therapies [OSTs], access to new direct active agents [DAAs], and/or HCV screening). C and D, The per-
centage of new HIV infections averted among PWID and NPWID, respectively, when the coverage of interventions against HIV transmission is increased (including NSP, OST, 
access to antiretroviral therapy [ART], and/or HIV screening). aIn Georgia and Kazakhstan, HIV screening currently being ≥90% among PWID, the increase of the coverage 
was not included in the strategies tested.
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Table 2. Cost-effectiveness Results Over 20 Years in Each Country
Strategiesb
Undiscounted 3% Discounted
ICERc ($/YLS)Total Costs (% Increase), $ YLS (‰ Increase)
Total
Costs, $ YLS
Belarus (GDP per capita = $7575)
 5) ART, DIAG HIV (90% vs 66%) 331 820 k (-5.0) 12 650 (+0.1) 249 570 k 7890 Cost-savingd
 4) ART (90% vs 67%) 340 050 k (-2.6) 4440 (+0.0) 253 730 k 2770 Cost-saving
 1) Baseline 349 220 k (ref) -- (ref) 259 700 k -- --
 0) Alternative scenario with 2005 
coverages
368 880 k (+5.6) -21 080 (-0.2) 269 600 k -13 220 Dominatede
 8) NSP, OST, ART, DIAG HIV 371 300 k (+6.3) 53 560 (+0.4) 279 810 k 34 900 210
 7) NSP, OST, ART 379 000 k (+8.5) 45 710 (+0.3) 283 670 k 30 000 Dominated
 3) NSP, OST (20% vs 1.2%) 387 500 k (+11.0) 41 500 (+0.3) 289 210 k 27 370 Dominated
 2) NSP (40% vs 8% at baseline) 390 560 k (+11.8) 1600 (+0.0) 291 220 k 980 Dominated
 6) ART, DIAG HIV, anti-HCV (50% vs 
0.001%)
383 640 k (+9.9) 17 350 (+0.1) 293 640 k 10 910 Dominated
 9) NSP, OST, ART, DIAG HIV, 
anti-HCV
416 790 k (+19.3) 58 250 (+0.4) 319 580 k 37 920 Ext. dominf
 10) ART, DIAG HIV, anti-HCV, DIAG 
HCV (75% vs 27%)
444 900 k (+27.4) 23 100 (+0.2) 348 050 k 14 620 Dominated
 11) NSP, OST, ART, DIAG HIV, anti-
HCV, DIAG HCV
466 850 k (+33.7) 63 830 (+0.5) 365 790 k 41 540 12 960
Georgia (GDP per capita = $3602)
 5) ART (90% vs 88%), DIAG HIVa 468 600 k (-0.1) 160 (+0.0) 350 180 k 100 Cost-saving
 1) Baseline 469 080 k (ref) -- (ref) 350 490 k -- --
 0) Alternative scenario with 2005 
coverages
484 390 k (+3.2) -15 730 (-0.3) 359 000 k -10 080 Dominated
 8) NSP, OST, ART, DIAG HIVa 482 520 k (+2.8) 17 530 (+0.3) 361 110 k 11 620 910
 3) NSP, OST (20% vs 5%) 482 940 k (+2.9) 17 390 (+0.3) 361 380 k 11 530 Dominated
 2) NSP (40% vs 6% at baseline) 483 920 k (+3.1) 630 (+0.0) 362 020 k 380 Dominated
 6) ART, anti-HCV (50% vs 0.001%) 553 000 k (+15.2) 4020 (+0.1) 421 710 k 2580 Dominated
 9) NSP, OST, ART, DIAG HIV,a 
anti-HCV
557 650 k (+15.9) 21 400 (+0.3) 426 360 k 14 100 26 230
 11) NSP, OST, ART, DIAG HIV,a anti-
HCV, DIAG HCV
647 810 k (+27.6) 26 000 (+0.4) 507 910 k 17 080 27 460
 10) ART, DIAG HIV,a anti-HCV, DIAG 
HCV (75% vs 27%)
663 000 k (+29.2) 8740 (+0.1) 517 430 k 5620 Dominated
Kazakhstan (GDP per capita = $13 172)
 8) NSP, OST, ART, DIAG HIVa 1 661 940 k (-6.9) 185 280 (+0.8) 1 237 040 k 118 680 Cost-saving
 3) NSP, OST (20% vs 0.2%) 1 710 180 k (-3.9) 160 720 (+0.7) 1 265 370 k 103 610 Cost-saving
 5) ART (90% vs 38%), DIAG HIVa 1 713 180 k (-3.7) 32 750 (+0.1) 1 267 570 k 19 940 Cost-saving
 0) Alternative scenario with 2005 
coverages
1 784 870 k (+0.4) -31 500 (-0.1) 1 301 450 k -19 320 Cost-saving
 1) Baseline 1 777 110 k (ref) -- (ref) 1 304 890 k -- --
 2) NSP (60% vs 37% at baseline) 1 776 030 k (-0.1) 7840 (+0.0) 1 307 680 k 4720 Ext. domin
 9) NSP, OST, ART, DIAG HIV,a 
anti-HCV
1 775 600 k (-0.1) 196 170 (+0.9) 1 338 410 k 125 680 270
 6) ART, anti-HCV (50% vs 0.001%) 1 888 810 k (+5.9) 43 910 (+0.2) 1 411 650 k 27 110 Dominated
 11) NSP, OST, ART, DIAG HIV,a anti-
HCV, DIAG HCV
2 002 450 k (+11.3) 210 090 (+0.9) 1 534 280 k 134 640 21 850
 10) ART, DIAG HIV,a anti-HCV, DIAG 
HCV (75% vs 27%)
2 258 080 k (+21.3) 58 580 (+0.3) 1 706 340 k 36 520 Dominated
Republic of Moldova (GDP per 
capita = $2230)
 5) ART, DIAG HIV (90% vs 66%) 349 310 k (-8.0) 7670 (+0.1) 256 900 k 4730 Cost-saving
 8) NSP, OST, ART, DIAG HIV 353 240 k (-6.8) 21 050 (+0.4) 260 180 k 13 510 Cost-saving
 4) ART (90% vs 46%) 359 910 k (-4.8) 4240 (+0.1) 263 000 k 2620 Cost-saving
 7) NSP, OST, ART 363 160 k (-3.9) 17 800 (+0.3) 265 870 k 11 500 Cost-saving
 6) ART, DIAG HIV, anti-HCV (50% vs 
0.001%)
367 310 k (-2.7) 9050 (+0.2) 272 220 k 5630 Cost-saving
 1) Baseline 377 210 k (ref) -- (ref) 273 800 k -- --
 9) NSP, OST, ART, DIAG HIV, 
anti-HCV
369 030 k (-2.2) 22 430 (+0.4) 274 000 k 14 400 10
HIV & HCV Infections Among PWID in EECA • OFID • 7
Sensitivity Analyses
Regarding uncertainties concerning key parameters, results 
were robust to sensitivity analyses in each country when we var-
ied inputs at baseline such as needle sharing rates, the propor-
tion of HIV and HCV–diagnosed PWID, the efficacy of OST in 
terms of reduction of injections, and the percentage of PWID 
reached by 100% NSP.
For alternative scenarios, when considering the decrease of 
cost of new DAAs to $900 per therapy, the strategies combin-
ing the increase of all interventions including HCV screening 
and access to new DAAs (Strategy 11)  became cost-effective 
in Tajikistan ($1890/YLS), very cost-effective in Belarus and 
Georgia ($540 and $2060/YLS), and cost-saving in Kazakhstan 
and Republic of Moldova compared with the baseline. Initiating 
treatment at fibrosis stage ≥F0 made the increase of all interven-
tions (Strategy 11) cost-effective if costs of new DAAs remained 
below $7030 in Belarus; $1750 in Georgia; $7440 in Kazakhstan; 
$2820 in Republic of Moldova; and $300 in Tajikistan 
(Supplementary Figure  1), and increased the number of new 
HCV infections averted by 14% in Belarus to 38% in Tajikistan 
overall. When considering the eligibility of ART for everyone, 
whatever the CD4 at diagnosis, strategies increasing NSP, OST, 
HIV screening, and access to ART (Strategy 8)  remained very 
cost-effective in Belarus, Georgia, Republic of Moldova, and 
Tajikistan ($1120, $1930, $360, and $660/YLS), and cost-saving 
in Kazakhstan, and they increased the number of new HIV infec-
tions averted by 8% in Kazakhstan to 51% in Georgia overall.
All results on sensitivity analyses are presented in 
Supplementary Tables 3–7.
DISCUSSION
This study illustrates that a drastic reduction in the incidence 
and prevalence of HCV and HIV epidemics in Georgia and 
Kazakhstan in the next 20  years cannot be achieved without 
an increase of combined intervention coverages among PWID, 
such as NSP, OST, HCV screening, and access to ART and new 
Strategiesb
Undiscounted 3% Discounted
ICERc ($/YLS)Total Costs (% Increase), $ YLS (‰ Increase)
Total
Costs, $ YLS
 3) NSP, OST (20% vs 1.6%) 379 220 k (+0.5) 13 910 (+0.3) 275 970 k 9090 Dominated
 2) NSP (40% vs 34% at baseline) 382 290 k (+1.3) 580 (+0.0) 277 850 k 350 Dominated
 0) Alternative scenario with 2005 
coverages
398 860 k (+5.4) -6220 (-0.1) 286 920 k -3860 Dominated
 11) NSP, OST, ART, DIAG HIV, anti-
HCV, DIAG HCV
388 590 k (+2.9) 24 080 (+0.5) 291 740 k 15 470 16 600
 10) ART, DIAG HIV, anti-HCV, DIAG 
HCV (75% vs 27%)
390 700 k (+3.5) 10 740 (+0.2) 292 760 k 6720 Dominated
Tajikistan (GDP per capita = $1037)
 0) Alternative scenario with 2005 
coverages
137 130 k (-16.1) -12 540 (-0.1) 96 770 k -7760 Cost-saving
 4) ART (90% vs 69%) 158 660 k (-0.4) 2100 (+0.0) 113 370 k 1290 Cost-saving
 5) ART, DIAG HIV (90% vs 63%) 158 700 k (-0.3) 6050 (+0.1) 113 610 k 3710 Cost-saving
 1) Baseline 159 250 k (ref) -- (ref) 113 680 k -- --
 6) ART, DIAG HIV, anti-HCV (50% vs 
0.001%)
163 790 k (+2.8) 7040 (+0.1) 117 290 k 4340 Ext. domin
 7) NSP, OST, ART 168 020 k (+5.2) 26 630 (+0.3) 120 460 k 17 180 Ext. domin
 8) NSP, OST, ART, DIAG HIV 168 110 k (+5.3) 30 200 (+0.3) 120 720 k 19 380 360
 3) NSP, OST (20% vs 1.2%) 168 560 k (+5.5) 24 900 (+0.3) 120 760 k 16 120 Dominated
 2) NSP (40% vs 25% at baseline) 170 490 k (+6.6) 1260 (+0.0) 122 010 k 760 Dominated
 9) NSP, OST, ART, HIV DIAG, NEW 
DAA
171 660 k (+7.2) 31 130 (+0.3) 123 400 k 19 970 4550
 10) ART, DIAG HIV, anti-HCV, DIAG 
HCV (75% vs 27%)
175 960 k (+9.5) 9220 (+0.1) 126 300 k 5710 Dominated
 11) NSP, OST, ART, DIAG HIV, anti-
HCV, DIAG HCV
179 090 k (+11.1) 33 080 (+0.3) 129 220 k 21 210 4690
Abbreviations: ART, antiretroviral therapy; DIAG, diagnosis; GDP, gross domestic product; NEW DAA, new direct active agent; NSP, needle-syringe program; OST, opioid substitution therapy; 
YLS, years of life saved.
aIn Georgia and Kazakhstan, HIV screening currently being ≥90% among PWID, the increase of the coverage was not included in these strategies.
bBaseline: current coverages, NSP, OST, ART, DIAG, NEW DAA, YLS, GDP.
cIncremental cost-effectiveness ratios in US dollar per years of life saved ($/YLS). Calculated from the 3% discounted outcomes; the comparator strategy is always the next smallest, not 
dominated, alternative.
dCost-saving: less expensive and more effective than the current strategy (baseline).
eDominated: less effective and more costly than some alternative strategies.
fExtendedly dominated: has an incremental cost-effectiveness ratio that is greater than that of a more effective strategy.
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DAAs, as well as HIV screening in addition in Belarus, Republic 
of Moldova, and Tajikistan. However, these strategies were asso-
ciated with high costs and unfavorable cost-effectiveness ratios 
in most of the countries studied, in particular Georgia, Republic 
of Moldova, and Tajikistan, because of the high cost of new 
DAAs. When considering a lower cost (based on the cost of new 
DAAs in Egypt in 2013), the full combined strategy would save 
the largest number of life years and would become very cost-ef-
fective in Belarus, Georgia, and Tajikistan, and even cost-saving 
in Kazakhstan and Republic of Moldova over 20  years com-
pared with current coverages in 2012/13, although the overall 
costs of this strategy remained high. Moreover, it suggested 
that initiating new DAAs regardless of fibrosis stages would 
also avoid even larger numbers of transmission and large num-
bers of life-years and remain cost-effective in Belarus, Georgia, 
Kazakhstan, and Republic of Moldova by 2033. However, in all 
scenarios, the impact of increasing access to new DAAs would 
be significant only if associated with the increase of the percent-
age of diagnosed PWID.
Increases of NSP and OST in particular would have a high 
impact on HCV and HIV transmission, and their use is funda-
mental to the fight against the HCV and HIV epidemics. It would 
have been cost-effective if we did not consider other combinations 
of interventions. However, adding more interventions, although 
associated with higher intervention costs, was even more effective 
by decreasing the number of infections, and therefore decreased 
the overall costs. Consequently, when other interventions were 
added to the picture, NSP+OST alone, being less effective, was 
associated with higher overall costs and was dominated.
Considering the UNAIDS Fast Track 2020 objectives [22], we 
show that access to ART to 90% of diagnosed PWID and HIV 
screening increase to 90% of infected PWID would have a high 
impact on HIV transmissions and would save costs when con-
sidering a 20-year horizon compared with the current coverage 
of these strategies in 2012/13. Consequently, combined increases 
of NSP, OST, access to ART, and HIV screening among PWID 
would be effective, very favorable in terms of cost-effectiveness 
ratios, and would even save costs in Georgia and Kazakhstan 
compared with coverages in 2012/13. These findings corrobor-
ate results of previous studies performed in EECA countries, 
such as that OST and ART to high levels among PWID were 
effective and very cost-effective [9] and that strategies expand-
ing NSP and HIV testing in addition were also cost-effective [8]. 
In 2012, a modeling study on HCV/HIV infection conducted in 
8 EECA countries by Wilson DP et al. also demonstrated that 
the increase of NSP among PWID was very cost-effective [13].
In 2013, HIV-screened patients in the countries studied 
initiated ART when the CD4 count dropped below 350 cells/
mm3, but new 2015 WHO guidelines now recommend that 
ART should be initiated regardless the CD4 cell count [23]. We 
have illustrated that it would avert HIV infections, save more 
years of life, and remain cost-effective when considering the 
increased access to ART combined with NSP, OST, and HIV 
screening compared with current strategies in Belarus, Georgia, 
Kazakhstan, and Republic of Moldova.
With regards to the general population, the strategies increas-
ing interventions in PWID had a low impact on HCV trans-
mission in non-PWID because of the very low risk of sexual 
transmission. However, the impact on HIV infection was more 
significant among non-PWID because the increased inter-
ventions among PWID reduced the risk of infection through 
unprotected sexual intercourse that PWID may have had with 
non-PWID.
Our study presents several limitations regarding uncertainty 
surrounding input data. First, regarding NSP, our model only 
considered PWID who had a full needle-syringe exchange; we 
assumed that this program has a significant impact on trans-
mission only when it reaches high distribution levels [15]. 
Consequently, we needed to estimate the proportion of PWID 
reached by 100% NSP from the total proportion of PWID 
reached by NSP in different countries. We varied the value of 
this key parameter, and the results remained robust to this var-
iation. Second, there was uncertainty regarding OST, and par-
ticularly its effectiveness in terms of reduction in the frequency 
of injections, but, again, the change in the effectiveness of OST 
did not affect the results. Moreover, we remained conserva-
tive because we could also consider that OST has an additional 
favorable impact on coverage of ART among HIV-infected 
PWID, as assessed in a recent meta-analysis by Low et al. [24]. 
Third, cost estimates were not fully available, in particular the 
costs of new DAAs. In the base case analysis, we used costs of 
past anti-HCV treatments available in countries at the time of 
our analysis. We decreased these costs in sensitivity analyses 
to evaluate the impact on the results of introducing DAAs at 
drastically lower cost. In addition to uncertainties concerning 
variables in this analysis, we used a simulation model that relies 
on multiple assumptions. However, extensive sensitivity analy-
ses were conducted, and the results were robust to alternative 
assumptions. The infectivity of those treated for HCV infection 
was considered uniform across fibrosis stages and age. Such 
considerations would have made the model much more com-
plex, and consequently would have had a negative impact on 
the validity of the model given that the population would have 
been even more compartmentalized, leading to more assump-
tions on parameters that are not really reported in the literature. 
We also assumed that disease progression did not change if an 
individual was HIV/HCV co-infected. This assumption may be 
correct only in treated HIV-infected patients with a high CD4 
count, which was not always the case in the model. We didn’t 
account for specific reinfection rates after spontaneous clear-
ance; individuals returned to susceptible states with the same 
probabilities of HCV infection and clearance [25]. Finally, this 
study was performed in 5 countries from a region where HIV 
and HCV epidemics are specifically important, in particular 
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among PWID, and conclusions on cost-effectiveness of such 
combined interventions may not be extrapolated to other 
regions of the world.
This study illustrates that OST and NSP combined with 
other interventions, such as access to treatments and screening, 
would have a high impact in terms of survival benefits while 
containing costs, not only from the perspective of PWID, but 
the overall population in 5 representative countries of Eastern 
Europe and Central Asia.
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